Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension

Journal of Human Hypertension

Volumn 24, Issue 6, 2010, Pages 403-409

  Izzo, J L ^a   Purkayastha, D ^b   Hall, D ^b   Hilkert, R J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amlodipine; Anti hypertensive treatment trial; Benazepril; Severe hypertension; Single pill combination therapy

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE CRAMP; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; CHRONIC DISEASE; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; EDEMA; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952424018     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.80     Document Type: Article

References (8)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
2. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006;7:61-63.
3. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: outcomes in Patients Receiving Monotherapy. Hypertension 2006;48:385-391.
4. The ALLHAT Officers and Coordinators for the ALL-HAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
5. Jamerson K, Weber MA, Bakris G, Dahlöf B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
6. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501.
7. Bakris GL, Weir MR, Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens 2003;5:202-209.
8. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens 2003;5:330-335.